Categories: All CategoriesCorporateProductsPipelineFinancial Jan 05, 2021Myriad Genetics Provides Transformation Update, Pursues Strategic Alternatives for Autoimmune Business, Realigns International OperationsCorporateJan 04, 2021Myriad Genetics CEO Paul J. Diaz to Present at 39th Annual J.P. Morgan Healthcare ConferenceCorporateOct 15, 2020Myriad Genetics Files Fiscal Year 2020 Proxy Statement, Implements Corporate Governance Changes In Support of Stakeholder InterestsCorporateSep 10, 2020Myriad Genetics Expands Board of Directors with New MemberCorporateAug 14, 2020Myriad Genetics Announces Inducement AwardsCorporateAug 13, 2020Myriad Genetics Appoints Paul J. Diaz as President and Chief Executive Officer and a Member of the Board of DirectorsCorporateAug 06, 2020Myriad to Announce Fiscal Fourth-Quarter and Full Fiscal Year 2020 Financial Results on August 13, 2020CorporateJul 22, 2020Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D.CorporateMay 28, 2020Myriad Genetics Appoints Daniel K. Spiegelman to the Board of Directors and Announces Upcoming Retirement of John T. Henderson, M.D.CorporateApr 28, 2020Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020CorporateMar 23, 2020Myriad Announces Board of Directors Leadership TransitionCorporateFeb 12, 2020Myriad Genetics to Present at the SVB Leerink Global Healthcare ConferenceCorporateFeb 06, 2020Myriad Announces Leadership TransitionCorporateJan 30, 2020Myriad to Announce Fiscal Second-Quarter 2020 Financial Results on February 6, 2020CorporateJan 14, 2020Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad OncologyCorporate Next page